SEC Filing Summary
Issuer and period: The supplied filing is Organovo Holdings, Inc.’s Form 10-Q for the quarter ended September 30, 2017, covering the second quarter and first six months of fiscal 2018. This differs from the request metadata, which names Vivosim Labs, Inc. and 2017 Q2. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless otherwise noted.
Business context
Organovo is an early commercial-stage company developing and selling 3D-printed human tissue products and research services for drug discovery and biological research, while pursuing therapeutic tissue applications. Its commercial offerings included ExVive Human Liver and Kidney tissue services and primary human cells and tissues.
Financial performance
| Metric | Three months ended Sep. 30, 2017 | Three months ended Sep. 30, 2016 | Six months ended Sep. 30, 2017 | Six months ended Sep. 30, 2016 |
|---|---|---|---|---|
| Revenue | $1.355 million | $1.376 million | $2.345 million | $2.266 million |
| Gross profit / margin | $1.101 million / 81.3% | $0.983 million / 71.4% | $1.790 million / 76.3% | $1.705 million / 75.2% |
| Operating loss | $(9.579) million | $(9.479) million | $(19.779) million | $(18.256) million |
| Net loss | $(9.461) million | $(9.442) million | $(19.563) million | $(18.209) million |
| Basic and diluted loss per share | $(0.09) | $(0.10) | $(0.19) | $(0.20) |
For the quarter, products and services revenue fell 10% year over year, while total revenue was nearly flat; higher-margin cell and tissue product sales helped lift gross margin. For the six months, products and services revenue rose 12%, but lower collaboration revenue largely offset that growth. R&D expense increased 9% in the quarter and 11% for the half; SG&A declined 3% in the quarter but rose 5% for the half.
Cash, liquidity and financing
- At September 30, 2017, cash and cash equivalents were $50.732 million, versus $62.751 million at March 31, 2017. Current assets were $53.344 million and current liabilities $4.125 million, implying working capital of $49.219 million.
- Operating cash use was $16.802 million for the six months, up from $14.909 million in the prior-year period. Investing cash use was $0.126 million; financing provided $4.909 million, primarily from ATM stock sales and option exercises.
- The balance sheet reports no borrowings or debt balance; interest paid was zero. Total liabilities were $4.853 million. Operating lease obligations totaled $4.903 million.
- Shares outstanding were 106.905 million at September 30, 2017. ATM sales generated approximately $4.0 million net during the half; $17.8 million remained available under the ATM program, and management reported $107.5 million of aggregate future offering capacity under the shelf registration statement.
Management said available resources and its current operating plan were sufficient to fund operations for at least 12 months from the financial statement issuance date. It also said additional capital would be needed to further fund development and commercialization, and warned that financing might not be available on acceptable terms; equity financing could dilute shareholders and debt could impose restrictive obligations.
Outlook, risks and notable items
- On October 4, 2017, the company announced a restructuring affecting approximately 15 positions, or 13% of its workforce. It expected a roughly $0.9 million charge in fiscal Q3 2018, mainly for severance and benefits, with actions expected to be completed by quarter-end.
- In July 2017, the NIH awarded a research grant of approximately $1.657 million, with payments tied to milestones; $149,000 of grant revenue was recognized in the quarter and half-year.
- The company highlighted risks around product and service adoption, continued operating losses, cash burn, and its ability to secure future financing. Revenue was concentrated among a relatively small number of customers and collaborators.
- Management reported no material changes to previously disclosed risk factors, no accrued legal loss contingencies, and no off-balance-sheet arrangements. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the issuer and reporting period: the filing identifies Organovo Holdings, Inc. and a quarter ended September 30, 2017, not Vivosim Labs, Inc. or a calendar 2017 second quarter.
- Track cash consumption against management’s stated 12-month funding runway, including the impact of the announced restructuring and continued development spending.
- Assess whether product and service growth can offset weaker collaboration revenue and support improved operating results.
- Review potential dilution from ATM issuance and outstanding equity awards; the filing reports substantial shares reserved or issuable under plans, awards and warrants.
- Monitor the NIH grant milestones, the restructuring charge, and the timing and terms of any future financing.